{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:55:42Z","timestamp":1780379742156,"version":"3.54.1"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL131579"],"award-info":[{"award-number":["R01 HL131579"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K24 HL159246"],"award-info":[{"award-number":["K24 HL159246"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K01 HL164764"],"award-info":[{"award-number":["K01 HL164764"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Direct oral anticoagulants (DOACs; namely, rivaroxaban and apixaban) and warfarin are approved for venous thromboembolism (VTE) treatment. Few direct comparisons exist of DOACs on risk of death among patients with VTE, and for patients with concomitant conditions (eg, kidney disease, liver disease), clinical guidelines are unclear. We evaluated 6-month all-cause mortality by anticoagulant prescribed for primary treatment of VTE. Using data from a 20% sample of Medicare beneficiaries, we created a propensity score\u2013matched analytic data set of 47\u2009860 beneficiaries with noncancer incident VTE. We used Cox regression to estimate adjusted hazard ratios (HRs) of OACs with 6-month mortality, and tested interactions by liver and kidney disease. There were 3422 deaths over 6\u00a0months of follow-up. In adjusted models, patients prescribed rivaroxaban (HR = 0.82; 95% CI, 0.76-0.90) had lower mortality rates than those prescribed warfarin. There was no association when comparing apixaban with warfarin (HR = 0.96; 95% CI, 0.87-1.07). In head-to-head comparisons of apixaban and rivaroxaban, the HR was 1.14 (95% CI, 1.01-1.28). Findings were similar among patients with liver and kidney disease. Overall, risk of death was similar by OAC prescribed. Though it is possible residual confounding remained, there was some suggestion of lower risk with rivaroxaban than warfarin. Treatment with DOACs appears safe among patients with VTE who have concomitant kidney or liver disease.<\/jats:p>\n               <jats:p>This article is part of a Special Collection on Pharmacoepidemiology.<\/jats:p>","DOI":"10.1093\/aje\/kwae268","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T07:47:11Z","timestamp":1723016831000},"page":"699-708","source":"Crossref","is-referenced-by-count":3,"title":["Association of anticoagulant choice with death in the primary treatment of noncancer venous thromboembolism: Medicare 2011-2018"],"prefix":"10.1093","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1151-3675","authenticated-orcid":false,"given":"Rob F","family":"Walker","sequence":"first","affiliation":[{"name":"School of Public Health, Division of Epidemiology and Community Health, University of Minnesota , Minneapolis, MN ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8824-4410","authenticated-orcid":false,"given":"Neil A","family":"Zakai","sequence":"additional","affiliation":[{"name":"Department of Medicine, Larner College of Medicine at the University of Vermont , Burlington, VT ,","place":["United States"]},{"name":"Department of Pathology and Laboratory Medicine, Larner College of Medicine at the University of Vermont , Burlington, VT ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2041-3710","authenticated-orcid":false,"given":"Richard F","family":"Maclehose","sequence":"additional","affiliation":[{"name":"School of Public Health, Division of Epidemiology and Community Health, University of Minnesota , Minneapolis, MN ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1975-0405","authenticated-orcid":false,"given":"Faye L","family":"Norby","sequence":"additional","affiliation":[{"name":"School of Public Health, Division of Epidemiology and Community Health, University of Minnesota , Minneapolis, MN ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2225-8323","authenticated-orcid":false,"given":"Alvaro","family":"Alonso","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Rollins School of Public Health, Emory University , Atlanta, GA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1572-1340","authenticated-orcid":false,"given":"Pamela L","family":"Lutsey","sequence":"additional","affiliation":[{"name":"School of Public Health, Division of Epidemiology and Community Health, University of Minnesota , Minneapolis, MN ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,9]]},"reference":[{"issue":"2","key":"2025100110312862500_ref1","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"issue":"19","key":"2025100110312862500_ref2","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv"},{"issue":"26","key":"2025100110312862500_ref3","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"issue":"14","key":"2025100110312862500_ref4","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"B\u00fcller","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"2025100110312862500_ref5","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"2025100110312862500_ref6","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/rth2.12222","article-title":"Direct oral anticoagulants and warfarin for venous thromboembolism treatment: trends from 2012 to 2017","volume":"3","author":"Lutsey","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"5","key":"2025100110312862500_ref7","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1111\/bjh.15857","article-title":"Risk of hospitalised bleeding in comparisons of oral anticoagulant options for the primary treatment of venous thromboembolism","volume":"185","author":"Lutsey","year":"2019","journal-title":"Br J Haematol"},{"issue":"4","key":"2025100110312862500_ref8","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12514","article-title":"Impact of oral anticoagulant choice for the secondary prevention of venous thromboembolism on the risk of inpatient bleeding","volume":"5","author":"MacLehose","year":"2021","journal-title":"Res Pract Thromb Haemost."},{"issue":"1","key":"2025100110312862500_ref9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.7326\/M21-0717","article-title":"Risk for recurrent venous thromboembolism and bleeding with apixaban compared with rivaroxaban: an analysis of real-world data","volume":"175","author":"Dawwas","year":"2022","journal-title":"Ann Intern Med"},{"issue":"11","key":"2025100110312862500_ref10","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1002\/ajh.25604","article-title":"Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism","volume":"94","author":"Wysokinski","year":"2019","journal-title":"Am J Hematol"},{"issue":"1","key":"2025100110312862500_ref11","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1161\/CIRCOUTCOMES.112.968826","article-title":"Consequences for healthcare quality and research of the exclusion of records from the Death Master Dile","volume":"6","author":"Graca","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"9","key":"2025100110312862500_ref12","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.2215\/CJN.10960917","article-title":"Clinical pharmacodynamics: principles of drug response and alterations in kidney disease","volume":"13","author":"Keller","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"2025100110312862500_ref13","doi-asserted-by":"publisher","first-page":"370","DOI":"10.2165\/00003088-199529050-00005","article-title":"Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease","volume":"29","author":"Morgan","year":"1995","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"2025100110312862500_ref14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.amjmed.2004.01.018","article-title":"Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology","volume":"117","author":"Cushman","year":"2004","journal-title":"Am J Med"},{"issue":"12","key":"2025100110312862500_ref15","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1097\/MLR.0000000000000524","article-title":"Validity of using inpatient and outpatient administrative codes to identify acute venous thromboembolism: the CVRN VTE Study","volume":"55","author":"Fang","year":"2017","journal-title":"Med Care"},{"issue":"4","key":"2025100110312862500_ref16","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.thromres.2015.01.012","article-title":"Improving accuracy of International Classification of Diseases codes for venous thromboembolism in administrative data","volume":"135","author":"Sanfilippo","year":"2015","journal-title":"Thromb Res"},{"issue":"3","key":"2025100110312862500_ref17","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/pds.2041","article-title":"Ascertainment of warfarin and aspirin use by medical record review compared with automated pharmacy data","volume":"20","author":"Garg","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025100110312862500_ref18","volume-title":"Death Information in the research identifiable Medicare data","author":"Jarosek","year":"2018"},{"issue":"11","key":"2025100110312862500_ref19","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"2025100110312862500_ref20","author":"Bergstralh","year":"2003"},{"issue":"4","key":"2025100110312862500_ref21","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"issue":"5","key":"2025100110312862500_ref22","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1097\/EDE.0000000000000864","article-title":"Web site and R package for computing E-values","volume":"29","author":"Mathur","year":"2018","journal-title":"Epidemiology"},{"issue":"9","key":"2025100110312862500_ref23","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1055\/s-0038-1668521","article-title":"All-cause mortality risk with direct oral anticoagulants and warfarin in the primary treatment of venous thromboembolism","volume":"118","author":"Roetker","year":"2018","journal-title":"Thromb Haemost"},{"issue":"23","key":"2025100110312862500_ref24","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1001\/jama.2021.21222","article-title":"Association of rivaroxaban vs apixaban with major ischemic or hemorrhagic events in patients with atrial fibrillation","volume":"326","author":"Ray","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"2025100110312862500_ref25","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1053\/j.ajkd.2010.05.013","article-title":"Validation of CKD and related conditions in existing data sets: a systematic review","volume":"57","author":"Grams","year":"2011","journal-title":"Am J Kidney Dis"}],"container-title":["American Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/aje\/advance-article-pdf\/doi\/10.1093\/aje\/kwae268\/58788101\/kwae268.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/aje\/article-pdf\/194\/3\/699\/58788101\/kwae268.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/aje\/article-pdf\/194\/3\/699\/58788101\/kwae268.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:31:33Z","timestamp":1759329093000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/aje\/article\/194\/3\/699\/7730939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,9]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,8,9]]},"published-print":{"date-parts":[[2025,3,4]]}},"URL":"https:\/\/doi.org\/10.1093\/aje\/kwae268","relation":{},"ISSN":["0002-9262","1476-6256"],"issn-type":[{"value":"0002-9262","type":"print"},{"value":"1476-6256","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,8,9]]}}}